Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 9/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550640 | 0.76 | ALDH1A1 (0.41) | L3MBTL1ALDH1A1 | |
| SCHEMBL2133548 | 0.75 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1 | |
| SCHEMBL13434086 | 0.74 | CCR5 (0.59) | L3MBTL1CCR5ALDH1A1 | |
| SCHEMBL10168839 | 0.74 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL4805068 | 0.73 | CCR5 (0.55) | L3MBTL1CCR5 | |
| SCHEMBL4805070 | 0.73 | CCR5 (0.55) | L3MBTL1CCR5 | |
| SCHEMBL633907 | 0.72 | SIGMAR1 (0.54) | L3MBTL1ALDH1A1 | |
| SCHEMBL633302 | 0.72 | SIGMAR1 (0.54) | L3MBTL1ALDH1A1 | |
| SCHEMBL13684267 | 0.71 | L3MBTL1 (0.63) | L3MBTL1CCR5 | |
| SCHEMBL11191249 | 0.70 | TDP1 (0.53) | L3MBTL1NAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | L3MBTL1 2853/4885CCR5 1016/4885NAAA 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.